Home Business Nobel laureate Doudna’s biotech Mammoth hits over $1 billion in valuation By...

Nobel laureate Doudna’s biotech Mammoth hits over $1 billion in valuation By Reuters

© Reuters. Nobel Prize in chemistry winner, American scientist Jennifer Doudna poses with her medal outside her house in Berkeley, California, U.S., in this undated handout image obtained by Reuters on December 9, 2020. Nobel Prize Outreach/Brittany Hosea-Small/Hand

By Manas Mishra

(Reuters) – Mammoth Biosciences, co-founded by Nobel laureate Jennifer Doudna, touched a valuation of more than $1 billion after raising $150 million in its latest funding round.

Doudna, who shared the 2020 Nobel Prize in Chemistry with Emmanuelle Charpentier for developing the CRISPR/CAS9 gene editing tool, co-founded the biotech startup in 2017, with a focus on using the technology to develop diagnostics.

The San Francisco-based company, which is using CRISPR to develop a COVID-19 test, said on Thursday it hopes the latest funding will allow it to double down on the development of therapeutics.

“We’ve always known that many of these proteins could be transformative for therapeutic applications as well,” said Chief Executive Officer Trevor Martin, who co-founded the company with Doudna and other members of her lab.

“In particular, what we are excited about (is) what we call permanent genetic cures.”

Martin said the discovery by Mammoth of newer and smaller proteins such as CAS14 could help overcome hurdles faced by older ones, including the CAS9 editing tool.

“These are compact cars compared to freight trucks of the existing previous technologies, and I think that’s transformative for delivering these technologies in-vivo (in the body).”

The company, which counts Apple Inc (NASDAQ:)’s Chief Executive Tim Cook and Alphabet (NASDAQ:)’s Verily as investors, declined to comment on a specific timeline for when a drug could begin being tested in humans.

Mammoth has rapidly expanded to 110 employees as recent funding helped in beefing up its clinical teams. In late 2020, the company raised $45 million in a funding round.

The latest series D funding round was led by healthcare-focused hedge fund Redmile Group and other participants included Foresite Capital and Senator Investment Group.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.